Table 2.
Disease | Action of Curcumin | Effects of Curcumin | Animal Model/Cell Type | Reference |
---|---|---|---|---|
Chronic kidney disease (CKD)-induced muscle atrophy | Inhibition of GSK-3β activity | Improves muscle function Higher ATP levels Suppressing mitochondrial membrane potential Decreases mitochondrial oxidative stress and increases antioxidant levels |
C57BL/6 mice | [117] |
Neurodegenerative disease | Inhibits GFAP, vimentin and Prdx6 upregulation | Suppresses oxidative stress-induced inflammation Alleviates apoptosis Suppresses mitochondrial fragmentation |
Human glioblastoma cell line -A172 Human astrocytes cell line derived from spinal cord- HA-sp |
[118] |
Insulin resistance in non-alcoholic fatty liver disease | Inhibits lipoapoptosis, ROS generation and ATP depletion | Lowers high free fatty acid-induced synthesizes of phosphoenol pyruvate carboxykinase (PEPCK) and glucose-6-phosphate Contributes cell survival Restores mitochondrial membrane potential |
Hepatocytes | [66] |
Hyperglycemia | Inhibits increased oxygen consumption and decreased nitric oxide levels | Decreased state 3 oxygen consumption rate Declines the levels of thiobarbituaric acid-reactive substances |
Female and male heterozygote non-diabetic db/+ mice | [119] |
Heart failure | Acts as an adjuvant therapy | Inhibits mitochondrial impairment Alleviates oxidative stress Decreases mitochondrial membrane potential collapse |
Male wistar rats | [120] |
Alzheimer’s disease | Protects β-amyloid protein | Enhances mitochondrial fusion activity Decreases fission machinery Increased biogenesis and synaptic proteins |
SHSY5Y cells | [56] |
Acute kidney injury | Suppresses NF-κB activation in reducing inflammation and stimulates NRF2/HO-1 signaling reduced mitochondrial dysfunction | Decline in the level of mitochondrial ROS Reduced mitochondrial fragmentation level Enhanced TCA cycle, mitochondrial biogenesis |
Human renal proximal tubular epithelial cell (TEC) line—HK2 | [121] |